Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
aTyr Pharma, Inc. (ATYR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: ATYR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $19.35
1 Year Target Price $19.35
| 7 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -13.16% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 472.61M USD | Price to earnings Ratio - | 1Y Target Price 19.35 |
Price to earnings Ratio - | 1Y Target Price 19.35 | ||
Volume (30-day avg) 11 | Beta 0.87 | 52 Weeks Range 1.48 - 5.98 | Updated Date 07/5/2025 |
52 Weeks Range 1.48 - 5.98 | Updated Date 07/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -39.82% | Return on Equity (TTM) -79.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 409254555 | Price to Sales(TTM) 1147.59 |
Enterprise Value 409254555 | Price to Sales(TTM) 1147.59 | ||
Enterprise Value to Revenue 132.17 | Enterprise Value to EBITDA -0.81 | Shares Outstanding 89004400 | Shares Floating 86984035 |
Shares Outstanding 89004400 | Shares Floating 86984035 | ||
Percent Insiders 2.23 | Percent Institutions 69.63 |
Upturn AI SWOT
aTyr Pharma, Inc.
Company Overview
History and Background
aTyr Pharma, Inc. was founded in 2003. It focuses on the discovery and development of medicines based on novel biological pathways.
Core Business Areas
- Protein-based therapeutics: Develops protein-based therapeutics for severe immune-mediated diseases. Lead candidate is efzofitimod for pulmonary sarcoidosis.
Leadership and Structure
John Mendlein, PhD, serves as Chairman of the Board. The company has a management team responsible for research, development, and operations. The organization is structured around research and clinical development functions.
Top Products and Market Share
Key Offerings
- Efzofitimod: Efzofitimod is a selective modulator of Neuropilin-2 (NRP2) designed to downregulate innate and adaptive immune responses in inflammatory diseases. It is in clinical development for pulmonary sarcoidosis. Market share is currently 0 due to pre-commercialization stage. Competitors include companies targeting sarcoidosis with different mechanisms of action (e.g., anti-TNF agents).
Market Dynamics
Industry Overview
The biopharmaceutical industry is competitive, with significant investment in research and development. The market for immune-mediated diseases is substantial and growing.
Positioning
aTyr Pharma focuses on novel pathways with efzofitimod and related compounds. They are targeting unmet needs in severe immune-mediated diseases.
Total Addressable Market (TAM)
The total addressable market for sarcoidosis and other immune-mediated diseases is estimated to be in the billions of dollars. aTyr Pharma's positioning with efzofitimod allows them to target a specific segment of this market.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting NRP2
- Lead candidate in clinical development (efzofitimod)
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on a single lead candidate
- Clinical trial risks and uncertainties
Opportunities
- Positive clinical trial results for efzofitimod
- Partnerships and collaborations with larger pharmaceutical companies
- Expansion of pipeline into other immune-mediated diseases
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and approval delays
- Failure of clinical trials
Competitors and Market Share
Key Competitors
- Johnson & Johnson (JNJ)
- AbbVie (ABBV)
- Bristol Myers Squibb (BMY)
Competitive Landscape
aTyr Pharma is a smaller company competing with larger pharmaceutical companies in the immune-mediated disease space. Its competitive advantage lies in its novel therapeutic approach targeting NRP2. Disadvantages include limited resources and reliance on a single lead candidate.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by preclinical and clinical development progress.
Future Projections: Future projections depend on the success of efzofitimod in clinical trials and potential regulatory approval. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing efzofitimod through clinical trials and exploring potential partnerships.
Summary
aTyr Pharma is a development-stage biopharmaceutical company with a novel therapeutic approach. The success of efzofitimod is critical to its future. The company faces significant clinical trial and regulatory risks and needs to manage its limited resources effectively. Positive clinical data and potential partnerships are key to its growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- aTyr Pharma's website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About aTyr Pharma, Inc.
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-05-07 | President, CEO & Director Dr. Sanjay S. Shukla M.D., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://atyrpharma.com |
Full time employees 56 | Website https://atyrpharma.com | ||
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.